Drug resistance is a major challenge in HIV treatment. Understanding how Dolutegravir addresses this issue is crucial for effective therapy.

Understanding HIV Resistance:
HIV can develop resistance to antiretroviral drugs through genetic mutations. When resistance develops, medications become less effective, leading to treatment failure.

Dolutegravir Resistance Profile:
Dolutegravir has a high genetic barrier to resistance, meaning the virus needs to accumulate multiple mutations before resistance develops. This is a significant advantage over earlier HIV medications.

Resistance Mutations:
The primary resistance mutations affecting Dolutegravir include R263K, G118R, and combinations with other INSTI mutations. However, these mutations are rare in treatment-naive patients.

Clinical Implications:
The high barrier to resistance means Dolutegravir-based regimens have lower rates of virologic failure compared to other antiretroviral combinations.

Preventing Resistance:
Adherence to treatment is the most important factor in preventing resistance. Taking medications consistently and as prescribed minimizes the risk of resistance development.

Resistance Testing:
Genotypic resistance testing should be performed before initiating therapy when possible, and when virologic failure occurs to guide treatment decisions.

Treatment Options with Resistance:
Even when some INSTI resistance is present, Dolutegravir may still be effective, especially at higher doses (50mg twice daily) or in combination with other active agents.

Future Considerations:
Ongoing surveillance of resistance patterns helps inform treatment guidelines and ensures Dolutegravir remains an effective option for HIV treatment.